With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients.

This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.